RxDoctor Payments Data

Jake Gurland, MD

Internal Medicine · Bayonne, NJNPI 1174028435

Payments from drug & device makers

$2,215in general payments, 2019–2025

Across 123 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$401
  • GSK$305
  • Novo Nordisk$192
  • Lilly USA, LLC$155
  • Pfizer$149
  • Viiv Healthcare Company$137
  • plus $876 from 27 others

What the payments were for

  • Food & beverage$2,215100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,215 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$239,652
Medicare patients
175
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide129$142,572
OzempicSemaglutide42$40,929
JardianceEmpagliflozin34$36,999
EliquisApixaban43$36,684
FarxigaDapagliflozin Propanediol34$29,805
XareltoRivaroxaban23$23,015
LinzessLinaclotide20$21,879
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,684
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,855
MyrbetriqMirabegron19$8,232
JanuviaSitagliptin Phosphate13$7,217
JentaduetoLinagliptin/Metformin Hcl13$6,403
Humalog Kwikpen U-200Insulin Lispro11$5,925
Advair HfaFluticasone Propion/Salmeterol13$5,279
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$3,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$155$142,572129 claims
AstraZenecaFarxiga, Breztri Aerosphere$401$42,65953 claims
Novo NordiskOzempic$192$40,92942 claims
PfizerEliquis$149$36,68443 claims
AbbVieLinzess, Synthroid$28$23,07544 claims
GSKTrelegy Ellipta$305$13,68418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Bayonne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →